Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

CRVS
Corvus Pharmaceuticals, Inc.
stock NASDAQ

At Close
Aug 5, 2026 3:59:55 PM EDT
13.94USD+0.072%(+0.01)738,924
11.53Bid   16.30Ask   4.77Spread
Pre-market
Aug 3, 2026 9:27:30 AM EDT
13.31USD-0.449%(-0.06)0
After-hours
Aug 4, 2026 4:00:30 PM EDT
13.92USD-0.072%(-0.01)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 14, 2022
08:07AM EST  The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake   Benzinga
Jan 13, 2022
06:30PM EST  Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.   GlobeNewswire Inc
Dec 13, 2021
09:17AM EST  Corvus Pharmaceuticals Says New Preclinical Data Highlights Potential For CPI-818 As Therapy For Acute Graft Versus Host Disease In Patients Receiving Bone Marrow Transplantation   Benzinga
09:00AM EST  New Preclinical Data Highlights Potential for CPI-818 (ITK   GlobeNewswire Inc
Dec 3, 2021
09:12AM EST  Cantor Fitzgerald Maintains Overweight on Corvus Pharmaceuticals, Raises Price Target to $8   Benzinga
Dec 1, 2021
10:26AM EST  Jefferies Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $8   Benzinga
Nov 12, 2021
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:18AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:17AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:16AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:15AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:14AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:12AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:10AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:09AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:00AM EST  Results in patients with relapsed refractory NSCLC and head and neck cancer demonstrate tumor reduction in patients treated with mupadolimab mono and combination therapy   GlobeNewswire Inc
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
Nov 2, 2021
05:08PM EDT  Corvus Pharmaceuticals To Present Updated Mupadolimab Data At 2021 Society For Immunotherapy Of Cancer Annual Meeting   Benzinga
10:23AM EDT  Corvus Pharmaceuticals Q3 EPS $(0.24) Up From $(0.33) YoY   Benzinga
Nov 1, 2021
04:05PM EDT  Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2021.   GlobeNewswire Inc
Oct 28, 2021
08:26AM EDT  The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug   Benzinga
Oct 27, 2021
04:43PM EDT  Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China   Benzinga
04:05PM EDT  Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals   GlobeNewswire Inc
Oct 25, 2021
07:30PM EDT  Angel Pharmaceuticals Announces Approval of IND Application in China for ITK   PR Newswire
Sep 27, 2021
06:43AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 6.15 A.M. EDT).   RTTNews
Sep 22, 2021
08:36AM EDT  Corvus Pharma 13G Filing From Tang Capital Partners Shows New 8.8% Stake In Co.   Benzinga
06:08AM EDT  Corvus Pharmaceuticals Announced Results Published Online in Medrxiv in 40 Patients From Covid-19 Randomized Controlled Study, Which Showed Primary and Secondary Endpoints Trend Toward More Favorable Outcome for Mupadolimab Treated Patients Vs. Placebo   Benzinga
06:00AM EDT  Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab treated patients vs. placebo   GlobeNewswire Inc
Sep 20, 2021
02:13PM EDT  Corvus Pharmaceuticals Option Alert: Oct 15 $5 Calls at the Ask: 314 @ $1.9 vs 5354 OI; Earnings 10/28 After Close [est] Ref=$6.38   Benzinga
06:05AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.35 A.M. EDT).   RTTNews
Sep 17, 2021
03:10PM EDT  Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet   Benzinga
12:28PM EDT  What's Going On With Corvus Pharmaceuticals Stock Today?   Benzinga
12:12PM EDT  Mid-Day Market Update: Crude Oil Falls Over 1%; Helbiz Shares Spike Higher   Benzinga
10:19AM EDT  Mid-Morning Market Update: Markets Down; US Consumer Sentiment Edges Higher   Benzinga
05:31AM EDT  The following are some of the stocks making big moves in Friday's pre-market trading (as of 5.10 A.M. EDT).   RTTNews
Sep 7, 2021
04:05PM EDT  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Companys management will participate in two upcoming investor conferences in September:   GlobeNewswire Inc
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
05:00PM EDT  Corvus Pharma Reports Investigational New Drug Application Accepted For Phase 1/1b Trial Of CPI-818 In China   Benzinga
05:00PM EDT  Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b   GlobeNewswire Inc
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 3, 2021
07:05AM EDT  Mizuho Maintains Neutral on Corvus Pharmaceuticals, Lowers Price Target to $3.5   Benzinga
Aug 2, 2021
04:24PM EDT  Corvus Pharmaceuticals Q2 EPS $(0.28) Up From $(0.36) YoY   Benzinga
04:05PM EDT  Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2021.   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 16, 2021
10:18AM EDT  UPDATE: Roth Capital On Corvus Pharmaceuticals: Firm Sees Termination Of Phase 3 Trial Of anti-CD73 Antibody Mupadolimab In Hypoxic Covid-19 Patients As 'Most Prudent Decision Co. Could Make' To Preserve Capital And Focus On Core Oncology Programs   Benzinga
10:16AM EDT  Roth Capital Maintains Buy Rating On Corvus Pharmaceuticals With $6 Price Target   Benzinga
08:09AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
07:02AM EDT  Corvus Pulls Plug On Mupadolimab COVID-19 Program With Candidate Now Prioritized In Oncology   Benzinga
06:10AM EDT  HC Wainwright & Co. Maintains Buy on Corvus Pharmaceuticals, Lowers Price Target to $6   Benzinga
Jul 15, 2021
04:10PM EDT  Corvus Pharmaceuticals Shares To Resume Trade At 4:35 p.m. EDT   Benzinga
04:07PM EDT  Corvus Says With Discontinuation Of Phase 3 Mupadolimab Study, Now Expects FY21 Net Cash Used In Operating Activities $35M-$37M, Down From Prior Expectation Of $46M-$48M   Benzinga
04:06PM EDT  Corvus Pharmaceuticals Discontinues Phase 3 Study Of Mupadolimab (Anti-CD73) For COVID-19, Citing Vaccine Effectiveness In Reducing Hospitalizations   Benzinga
04:05PM EDT  Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies in an expansion cohort for patients with HPV+ (human papilloma virus) head and neck cancer   GlobeNewswire Inc
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jun 22, 2021
11:08AM EDT  Corvus Pharmaceuticals Granted U.S. Patent Titled 'Methods of treating cancer'   Benzinga
May 27, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021   Benzinga
09:54AM EDT  Corvus Pharmaceuticals Files For Patent Application Titled 'METHODS OF TREATING CANCER'   Benzinga
07:28AM EDT  Cantor Fitzgerald Initiates Coverage On Corvus Pharmaceuticals with Overweight Rating, Announces Price Target of $10   Benzinga
May 25, 2021
04:05PM EDT  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on Thursday, June 3, 2021 from 4:00-4:25 pm ET.   GlobeNewswire Inc
May 19, 2021
07:30AM EDT  The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics   Benzinga
May 18, 2021
07:44AM EDT  The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 6, 2021
09:41AM EDT  Given the rising number of daily coronavirus cases in some countries, the emergence of new variants, and waning immunity, it is for sure that COVID-19 will be an ongoing global public health concern. As of this writing, 155.3 million cases have been reported across the world, with the death tally crossing 3.24 million.   RTTNews
May 5, 2021
09:00AM EDT  Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximately $10 million of its common shares pursuant to the Companys ATM program established on March 9, 2020 through Jefferies LLC (Jefferies), acting as sales agent.   GlobeNewswire Inc
Apr 29, 2021
04:26PM EDT  Corvus Pharmaceuticals Q1 EPS $(0.34) Up From $(0.44) YoY   Benzinga
Mar 26, 2021
06:24AM EDT  HC Wainwright & Co. Maintains Buy on Corvus Pharmaceuticals, Lowers Price Target to $9.5   Benzinga
Mar 25, 2021
08:46AM EDT  Corvus Pharmaceuticals Q4 EPS $0.92 Up From $(0.38) YoY   Benzinga
08:30AM EDT  Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2020.   GlobeNewswire Inc
Mar 5, 2021
08:30AM EST  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Companys management will participate in two upcoming investor conferences in March:   GlobeNewswire Inc
Feb 20, 2021
02:17PM EST  The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More   Benzinga
Feb 18, 2021
08:14AM EST  The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout   Benzinga
Feb 17, 2021
04:49PM EST  Corvus Pharmaceuticals CEO Richard Miller Reported Purchase of 100,000 Shares @ Avg Price of $3.50/Share in Form 4 Filing   Benzinga
04:10PM EST  Corvus Pharmaceuticals Announces Closing of Public Offering of   GlobeNewswire Inc
Feb 12, 2021
09:47AM EST  Corvus Pharma Shares Drop After $30M Equity Raise At 11% Discount   Benzinga
09:01AM EST  Corvus Pharmaceuticals Prices 8,571,429 Share Common Stock Offering At $3.50/Share   Benzinga
09:00AM EST  Corvus Pharmaceuticals Announces Pricing of Public Offering of   GlobeNewswire Inc
Feb 11, 2021
04:07PM EST  Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock; No Terms Disclosed   Benzinga
04:01PM EST  Corvus Pharmaceuticals Announces Proposed Public Offering of   GlobeNewswire Inc
Feb 10, 2021
10:05AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021   Benzinga
08:01AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
06:54AM EST  Mizuho Downgrades Corvus Pharmaceuticals to Neutral, Lowers Price Target to $4   Benzinga
Feb 4, 2021
09:57AM EST  Corvus Initiates CPI-006 Pivotal Trial In COVID-19 Patients; Results Expected by 2021 End   Benzinga
07:32AM EST  Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial Of CPI-006 For Patients With COVID-19   Benzinga
07:30AM EST  Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure   GlobeNewswire Inc
Dec 6, 2020
10:00AM EST  Updated interimdata from CPI-818sphase 1/1b clinical trial provide evidence supporting its potential as a treatment for T cell lymphomas   GlobeNewswire Inc
Nov 30, 2020
08:00AM EST  Corvus Announces Upcoming CPI-818 Data Presentations at the   GlobeNewswire Inc
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 11, 2020
04:09PM EST  Corvus Hosting R&D Symposium On November 12 To Highlight COVID-19 Program And Updated Study Data Presented At SITC Annual Meeting   Benzinga
04:05PM EST  Data shows CPI-006 provided enhanced and prolonged polyclonal humoral immunity to SARS-CoV-2   GlobeNewswire Inc
Nov 9, 2020
08:06AM EST  Corvus Reports Completion Of Enrollment In Phase 1 Study Of CPI-006 For Patients With COVID-19, Presents Study Data At 2020 Society For Immunotherapy For Cancer Meeting   Benzinga
08:05AM EST  Data to be presented in a poster and an oral session Hot Topic Symposium COVID-19 and Cancer at SITC   GlobeNewswire Inc
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 2, 2020
08:13AM EST  Corvus Pharma Reports Its COVID-19 Abstract Selected For 'Hot Topic' Oral Session At 2020 Society For Immunotherapy Of Cancer Annual Meeting   Benzinga
08:00AM EST  Corvus Pharmaceuticals COVID-19 Abstract Selected for   GlobeNewswire Inc
Oct 29, 2020
04:00PM EDT  Corvus Pharma Q3 Loss $9.8M   Benzinga
08:48AM EDT  Corvus Pharma Will Present Updated Data From Trial Of CPI-006 For Patients With COVID-19 At Society For Immunotherapy Of Cancer Meeting Nov. 12   Benzinga
08:37AM EDT  Corvus To Present Updated Data From Phase 1 Study Investigating Potential For CPI-006 At SITC   RTTNews
08:30AM EDT  Corvus Pharmaceuticals, Inc.(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present updated data from its Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place November 9-14, 2020.   GlobeNewswire Inc
Oct 6, 2020
08:08AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:30AM EDT  HC Wainwright & Co. Maintains Buy on Corvus Pharmaceuticals, Raises Price Target to $12   Benzinga
Oct 5, 2020
02:39PM EDT  Mid-Afternoon Market Update: Dow Surges 350 Points; Eidos Therapeutics Shares Spike Higher   Benzinga
12:12PM EDT  Mid-Day Market Update: Crude Oil Jumps 7%; Nam Tai Property Shares Plunge   Benzinga
10:33AM EDT  Shares of Corvus Pharmaceuticals, Inc. (CRVS) jumped nearly 30% on Monday morning after the drug maker reported positive results from an early stage study of investigational COVID-19 treatment.   RTTNews
09:48AM EDT  Looking Into Corvus Pharmaceuticals's Return On Capital Employed   Benzinga
08:40AM EDT  Shares of Corvus Pharmaceuticals Inc. (CRVS) surged in the pre-market trading on Monday after the company unveiled positive results from an early stage study of its developing COVID-19 treatment.   RTTNews
07:54AM EDT  Corvus Pharmaceuticals Inc. (CRVS) said it will initially retain a 49.7% equity stake in Angel Pharmaceuticals and will be entitled to designate three individuals on Angel's five-person Board of Directors, as part of a collaboration between them.   RTTNews
07:28AM EDT  Corvus Enters Into Strategic Collaboration With Angel Pharmaceuticals   RTTNews
07:26AM EDT  Corvus: New Data From Phase 1 Study Of CPI-006 Continues To Support Potential As COVID-19 Treatment   RTTNews
07:25AM EDT  Corvus Says 'Dose-response effect seen in first two cohorts with prolonged high titers of antibodies observed out to 56 days'   Benzinga
07:24AM EDT  Angelspipeline will feature Corvus three clinical-stage candidates ciforadenant, CPI-006 and CPI-818 and its preclinical BTK inhibitor program   GlobeNewswire Inc
07:24AM EDT  Corvus Pharmaceuticals Announces Updated Data From Phase 1 Study Of CPI-006 In COVID-19   Benzinga
07:22AM EDT  Enrollment in first three cohorts complete; final cohort now enrollingwith plans to initiate a pivotal study before year-end   GlobeNewswire Inc
Sep 17, 2020
03:01AM EDT  Data is part of Genentechs MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with atezolizumab   GlobeNewswire Inc
Sep 11, 2020
08:30AM EDT  Corvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of   GlobeNewswire Inc
Sep 10, 2020
09:30AM EDT  Biopharmaceutical company Corvus Pharmaceuticals, Inc. (CRVS) announced Thursday updated data from its ongoing Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for patients with COVID-19.   RTTNews
08:40AM EDT  Corvus Pharma Provides Update On Clinical Trial Of CPI-006 For Patients With COVID-19   RTTNews
08:32AM EDT  Corvus Pharmaceuticals Provides Update On Clinical Trial Of CPI-006 For Patients With Coronavirus; Patients Treated In First Two Cohorts Of Phase 1 Study Had Low Pre-Treatment Titers Of Antibodies, Produced Robust Antibody Response Within 7 Days   Benzinga
08:32AM EDT  Corvus Pharmaceuticals Says Patients Treated In First Two Cohorts Of Phase 1 Study Of CPI-006 For COVID-19 Had Low Pre-Treatment Titers Of Antibodies And Produced Robust Antibody Responses Within 7 Days Of Treatment   Benzinga
08:30AM EDT  Characterization of novel immunotherapy approach with CPI-006 and details of COVID-19 clinical trial results submitted for publication online at medRxiv.org   GlobeNewswire Inc
Sep 8, 2020
06:02PM EDT  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following investor conferences:   GlobeNewswire Inc
Aug 4, 2020
04:05PM EDT  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will be on Tuesday, August 11 from 2:55-3:25pm ET.   GlobeNewswire Inc
Jul 30, 2020
04:06PM EDT  Corvus Pharmaceuticals Q2 EPS $(0.36) Misses $(0.28) Estimate   Benzinga
04:06AM EDT  Earnings Scheduled For July 30, 2020   Benzinga
Jul 23, 2020
08:30AM EDT  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2020 financial results.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC